Investors

We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.

/assets/dotcom/content-app/events/banner-investors-events_20230703194346.jpg

First Quarter 2025

First quarter 2025 results were reviewed by management during a live audio webcast with the financial community. The presentation was followed by a Q&A session.

Thursday April 24, 2025

Press Releases


June 23, 2025
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-eligible newly diagnosed multiple myeloma

June 20, 2025
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

June 17, 2025
Press release: Sanofi successfully prices €1.5 billion bond issue

Upcoming Events

19Jun

2025

JPM European Healthcare Forum

08:00 - 15:00 GMT (London)

Conferences


31Jul

2025

Second Quarter 2025

Second quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation will be followed by a Q&A session.

15:00 - 16:30 CET (9:00am – 10:30am EDT)

Quarterly results


24Oct

2025

Third Quarter 2025

Third quarter 2025 results will be reviewed by management during a live audio webcast with the financial community on October 24, 2025. The presentation will be followed by a Q&A session.

14:30 - 16:00 CET (8:30am – 10am EDT)

Quarterly results


Karine Roblot, wearing a light green protective suit, operating steel equipment with lots of valves, gauges and tubing
Karine Roblot, Vaccine Formulation Technician, Val de Reuil, France

2024 20-F

Presenting our 2024 FORM 20-F.

30th Consecutive Year of Dividend Increase

Dr. Lingaraju checks the health of Manikantan as his sister Geetha watches closely inside the Billigiri Ranganathaswamy Temple Tiger Reserve in Chamrajanagara district, Karnataka state, India

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.

Contact Our Investor Relations Team

For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00